BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta Pharm Sin B 2021;11:2150-71. [PMID: 34522582 DOI: 10.1016/j.apsb.2021.05.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Brlecic PE, Bonham CA, Rosengart TK, Mathison M. Direct cardiac reprogramming: A new technology for cardiac repair. J Mol Cell Cardiol 2023:S0022-2828(23)00053-6. [PMID: 36965701 DOI: 10.1016/j.yjmcc.2023.03.008] [Reference Citation Analysis]
2 Breier D, Peer D. Genome editing in cancer: Challenges and potential opportunities. Bioactive Materials 2023;21:394-402. [DOI: 10.1016/j.bioactmat.2022.08.013] [Reference Citation Analysis]
3 Onuma H, Sato Y, Harashima H. Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing. J Control Release 2023;355:406-16. [PMID: 36773957 DOI: 10.1016/j.jconrel.2023.02.008] [Reference Citation Analysis]
4 Khirallah J, Eimbinder M, Li Y, Xu Q. Clinical progress in genome-editing technology and in vivo delivery techniques. Trends Genet 2023;39:208-16. [PMID: 36669950 DOI: 10.1016/j.tig.2022.12.001] [Reference Citation Analysis]
5 Ahmadi SE, Soleymani M, Shahriyary F, Amirzargar MR, Ofoghi M, Fattahi MD, Safa M. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. Cancer Gene Ther 2023;:1-19. [PMID: 36854897 DOI: 10.1038/s41417-023-00597-z] [Reference Citation Analysis]
6 Wong KH, Guo Z, Law MK, Chen M. Functionalized PAMAM constructed nanosystems for biomacromolecule delivery. Biomater Sci 2023;11:1589-606. [PMID: 36692071 DOI: 10.1039/d2bm01677j] [Reference Citation Analysis]
7 Oh CY, Henderson E. In vitro transcription of self-assembling DNA nanoparticles.. [DOI: 10.21203/rs.3.rs-2518372/v1] [Reference Citation Analysis]
8 Seo H, Jeon L, Kwon J, Lee H. High-Precision Synthesis of RNA-Loaded Lipid Nanoparticles for Biomedical Applications. Adv Healthc Mater 2023;:e2203033. [PMID: 36737864 DOI: 10.1002/adhm.202203033] [Reference Citation Analysis]
9 Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther 2023;8:36. [PMID: 36646687 DOI: 10.1038/s41392-023-01309-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mohammadian Gol T, Ureña-Bailén G, Hou Y, Sinn R, Antony JS, Handgretinger R, Mezger M. CRISPR medicine for blood disorders: Progress and challenges in delivery. Front Genome Ed 2022;4:1037290. [PMID: 36687779 DOI: 10.3389/fgeed.2022.1037290] [Reference Citation Analysis]
11 Leal AF, Fnu N, Benincore-Flórez E, Herreño-Pachón AM, Echeverri-Peña OY, Alméciga-Díaz CJ, Tomatsu S. The landscape of CRISPR/Cas9 for inborn errors of metabolism. Mol Genet Metab 2023;138:106968. [PMID: 36525790 DOI: 10.1016/j.ymgme.2022.106968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Schmidt TJN, Berarducci B, Konstantinidou S, Raffa V. CRISPR/Cas9 in the era of nanomedicine and synthetic biology. Drug Discov Today 2023;28:103375. [PMID: 36174966 DOI: 10.1016/j.drudis.2022.103375] [Reference Citation Analysis]
13 Wilton-Clark H, Yokota T. Biological and genetic therapies for the treatment of Duchenne muscular dystrophy. Expert Opin Biol Ther 2023;23:49-59. [PMID: 36409820 DOI: 10.1080/14712598.2022.2150543] [Reference Citation Analysis]
14 Guo H, Huang X. Engineered exosomes for future gene-editing therapy. Biomater Transl 2022;3:240-2. [PMID: 36846508 DOI: 10.12336/biomatertransl.2022.04.003] [Reference Citation Analysis]
15 Huang K, Zapata D, Tang Y, Teng Y, Li Y. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. Biomaterials 2022;291:121876. [PMID: 36334354 DOI: 10.1016/j.biomaterials.2022.121876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li Q, Gao Y, Wang H. CRISPR-Based Tools for Fighting Rare Diseases. Life (Basel) 2022;12. [PMID: 36556333 DOI: 10.3390/life12121968] [Reference Citation Analysis]
17 Bhattacharjee R, Jana A, Nandi A, Sinha A, Bhattacharjee A, Mitra S, Kar S, Dey A, Kumar Singh S, Rajender Varma S, Kumar Panda P, Suar M, Suresh Verma K. Synergy of Nanocarriers with CRISPR-Cas9 in an Emerging Technology Platform for Biomedical Appliances: Current Insights and Perspectives. Materials & Design 2022. [DOI: 10.1016/j.matdes.2022.111415] [Reference Citation Analysis]
18 Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, He W. Lipid carriers for mRNA delivery. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.026] [Reference Citation Analysis]
19 Godbout K, Tremblay JP. Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy. Pharmaceutics 2022;14:2129. [PMID: 36297564 DOI: 10.3390/pharmaceutics14102129] [Reference Citation Analysis]
20 Zhao M, Wang R, Yang K, Jiang Y, Peng Y, Li Y, Zhang Z, Ding J, Shi S. Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.10.019] [Reference Citation Analysis]
21 Arriaga-canon C, Contreras-espinosa L, Rebollar-vega R, Montiel-manríquez R, Cedro-tanda A, García-gordillo JA, Álvarez-gómez RM, Jiménez-trejo F, Castro-hernández C, Herrera LA. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. IJMS 2022;23:11058. [DOI: 10.3390/ijms231911058] [Reference Citation Analysis]
22 Li Y, Chen Z, Duan X, Zhang H, Xiao B, Wang K, Chen G. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer. Exp Mol Med. [DOI: 10.1038/s12276-022-00856-3] [Reference Citation Analysis]
23 Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv 2022;8:eabp9435. [DOI: 10.1126/sciadv.abp9435] [Reference Citation Analysis]
24 Liu Z, Li Z, Li B. Nonviral Delivery of CRISPR/Cas Systems in mRNA Format. Advanced NanoBiomed Research 2022. [DOI: 10.1002/anbr.202200082] [Reference Citation Analysis]
25 Getahun YA, Ali DA, Taye BW, Alemayehu YA. Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System. VMRR 2022;Volume 13:173-190. [DOI: 10.2147/vmrr.s366533] [Reference Citation Analysis]
26 Mariot V, Dumonceaux J. Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy. Front Genome Ed 2022;4. [DOI: 10.3389/fgeed.2022.937879] [Reference Citation Analysis]
27 Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, Zhang H, Cui W. Progress of delivery methods for CRISPR-Cas9. Expert Opin Drug Deliv 2022. [PMID: 35818792 DOI: 10.1080/17425247.2022.2100342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kayesh MEH, Hashem MA, Kohara M, Tsukiyama-kohara K. In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update. Front Microbiol 2022;13:953218. [DOI: 10.3389/fmicb.2022.953218] [Reference Citation Analysis]
29 Li Z, Pan Y, Du S, Li Y, Chen C, Song H, Wu Y, Luan X, Xu Q, Guan X, Song Y, Han X. Tumor-microenvironment activated duplex genome-editing nanoprodrug for sensitized near-infrared titania phototherapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.06.016] [Reference Citation Analysis]
30 Zambon A, Averna M, D’erasmo L, Arca M, Catapano A. New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.02.004] [Reference Citation Analysis]
31 Park SB, Uchida T, Tilson S, Hu Z, Ma CD, Leek M, Eichner M, Hong SG, Liang TJ. A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells. Mol Ther Nucleic Acids 2022;28:656-69. [PMID: 35615005 DOI: 10.1016/j.omtn.2022.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tang SC, Vijayakumar U, Zhang Y, Fullwood MJ. Super-Enhancers, Phase-Separated Condensates, and 3D Genome Organization in Cancer. Cancers (Basel) 2022;14:2866. [PMID: 35740532 DOI: 10.3390/cancers14122866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Yu W, Xuan C, Liu B, Zhou L, Yin N, Gong E, Zhang Z, Li Y, Zhang K, Shi J. Carrier-free programmed spherical nucleic acid for effective ischemic stroke therapy via self-delivery antisense oligonucleotide. Nano Res . [DOI: 10.1007/s12274-022-4402-7] [Reference Citation Analysis]
34 Asmamaw Mengstie M. Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Front Bioeng Biotechnol 2022;10:895713. [DOI: 10.3389/fbioe.2022.895713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Das S, Bano S, Kapse P, Kundu GC. CRISPR based therapeutics: a new paradigm in cancer precision medicine. Mol Cancer 2022;21:85. [PMID: 35337340 DOI: 10.1186/s12943-022-01552-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Kocher T, Petkovic I, Bischof J, Koller U. Current developments in gene therapy for epidermolysis bullosa. Expert Opin Biol Ther 2022. [PMID: 35235467 DOI: 10.1080/14712598.2022.2049229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Liu X, Wang Y, Effah CY, Wu L, Yu F, Wei J, Mao G, Xiong Y, He L. Endocytosis and intracellular RNAs imaging of nanomaterials-based fluorescence probes. Talanta 2022;243:123377. [DOI: 10.1016/j.talanta.2022.123377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Rafii S, Tashkandi E, Bukhari N, Al-Shamsi HO. Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges. Cancers (Basel) 2022;14:947. [PMID: 35205694 DOI: 10.3390/cancers14040947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Lin M, Yang Z, Yang Y, Peng Y, Li J, Du Y, Sun Q, Gao D, Yuan Q, Zhou Y, Chen X, Qi X. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today 2022;42:101359. [DOI: 10.1016/j.nantod.2021.101359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
40 Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Control Release 2022:S0168-3659(22)00027-X. [PMID: 35026352 DOI: 10.1016/j.jconrel.2022.01.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
41 Jacob EM, Borah A, Sakthi Kumar D. CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy. Nanotechnology in the Life Sciences 2022. [DOI: 10.1007/978-3-031-12658-1_2] [Reference Citation Analysis]
42 Kanduri V, LaVigne D, Larsen J. Current Advances Toward the Encapsulation of Cas9. ACS Macro Lett 2021;10:1576-89. [PMID: 35549133 DOI: 10.1021/acsmacrolett.1c00538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Walker HE, Rizzo M, Fras Z, Jug B, Banach M, Penson PE. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. Metabolites 2021;11:857. [PMID: 34940615 DOI: 10.3390/metabo11120857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Luo S, Wang Y, Tao Y, Li S, Wang Z, He W, Wang H, Wang N, Xu J, Song H. Application in Gene Editing in Ovarian Cancer Therapy. Cancer Invest 2021;:1-13. [PMID: 34758691 DOI: 10.1080/07357907.2021.1998521] [Reference Citation Analysis]
45 Lv Y, He W, Wu W. Editorial of Special Issue of Hot Topic Reviews in Drug Delivery. Acta Pharm Sin B 2021;11:2094-5. [PMID: 34522578 DOI: 10.1016/j.apsb.2021.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]